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Abstract
Purpose Anxiolytics and hypnotics are widely used and may
cause injurious falls. We aimed to examine associations be-
tween exposure to anxiolytics and hypnotics and the risk of
hip fracture among all older people in Norway. Further, we
wanted to examine associations between exposure to hyp-
notics and time of fracture.
Methods A nationwide prospective cohort study of people in
Norway born before 1945 (n=906,422) was conducted. We
obtained information on all prescriptions of anxiolytics and
hypnotics dispensed in 2004–2010 (the Norwegian
Prescription Database) and all primary hip fractures in
2005–2010 (the Norwegian Hip Fracture Registry). We com-
pared the incidence rates of hip fracture during drug exposure
and non-exposure by calculating the standardized incidence
ratio (SIR).
Results Altogether, 39,938 people (4.4 %) experienced a pri-
mary hip fracture. The risk of hip fracture was increased for
people exposed to anxiolytics (SIR 1.4, 95 % confidence
interval (CI) 1.4–1.5) and hypnotics (SIR 1.2, 95 % CI 1.1–
1.2); the excess risk was highest regarding short-acting ben-
zodiazepine anxiolytics (SIR 1.5, 95 % CI 1.4–1.6).
Benzodiazepine-like hypnotics (z-hypnotics) were associated
with higher excess risk of hip fracture at night (SIR 1.3, 95 %
CI 1.2–1.4) than during the day (SIR 1.1, 95 % CI 1.1–1.2).
Conclusions Older people had an increased risk of hip frac-
ture during anxiolytic or hypnotic drug use, including short-
acting benzodiazepine anxiolytics and z-hypnotics that were
previously considered less harmful; cautious prescribing is
therefore needed. People using z-hypnotics were at greatest
excess risk at night; this association deserves further
investigation.
Keywords Anxiolytics . Hypnotics . Hip fracture . Time of
fracture . Pharmacoepidemiology . Population-based registry
Introduction
Hip fractures are highly prevalent among older people, with
great implications for morbidity and mortality [1, 2]. Thus,
identifying and reducing modifiable risk factors are essential.
Anxiolytics (drugs that reduce anxiety, mainly benzodiaze-
pines) and hypnotics (drugs that reduce sleep disturbances,
mainly benzodiazepine-like drugs, z-hypnotics: zolpidem,
zopiclone and zaleplon) independently increase the risk of
falling because of sedation, impaired balance and impaired
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cognition [3–5]. Benzodiazepines have been associated with
increased risk of hip fracture, but estimates diverge [6–10]. Z-
hypnotics have previously been considered less harmful [11],
but growing evidence suggests that they are not safer than
benzodiazepines regarding either falls [12] or hip fractures
[13, 14].
Use of anxiolytic and hypnotic drugs increases with age,
and these drugs are commonly used by people most prone to
adverse drug effects and hip fractures [15, 16]. Long-term use
is widespread [16] although advised against [17]. In Norway,
15 % of the people aged 70 years or older receive at least one
anxiolytic drug prescription yearly [18]; overall, European
numbers range from 10 % (community dwellers) to 55 %
(nursing home patients) [19–23]. Hypnotics (mostly z-
hypnotics) are prescribed to 26 % of the people in Norway
70 years or older and to 52% of those older than 90 years [18],
in accordance with studies in Europe [15, 21] and the USA
[24]. Knowledge is scarce regarding associations between the
use of hypnotics and the time of hip fracture.
We conducted a prospective cohort study to examine asso-
ciations between exposure to anxiolytics and hypnotics and
the risk of hip fracture among the whole population of Norway
aged 60 years and older in 2005–2010. If we found associa-
tions, we would aim to estimate the attributable risk of hip
fracture. Further, we wanted to examine associations between
exposure to hypnotics and the time of hip fracture.
Methods
Design
We performed a nationwide prospective cohort study based on
merged data from the Norwegian Prescription Database
(NorPD) [25], the Norwegian Hip Fracture Registry [26] and
the Central Population Registry [27]. The study period lasted
from January 1, 2005, to December 31, 2010. The data
sources and methods have previously been described in detail
[28, 29].
Data sources
The NorPD was established in January 2004 [25]. It contains
information on all prescription drugs purchased by individual
patients at all pharmacies in Norway. The NorPD does not
contain indications for prescriptions or individual information
on medication dispensed to people living in nursing homes
(about 40,000 at any time—4.4 % of the study population).
The following data were extracted: all prescriptions of anxio-
lytics and hypnotics dispensed from January 1, 2004 (pre-
scriptions from 2004 necessary to be able to identify the users
when the study started), until December 31, 2010, to people
born before 1945 by the items’ generic name, Anatomical
Therapeutic Chemical (ATC) system code [30] and defined
daily dose (DDD) [30]. In Norway, all anxiolytics and hyp-
notics are prescription drugs only.
The Norwegian Hip Fracture Registry was established in
January 2005 [26]. This national registry contains information
about fractures and surgery performed on people for hip
fracture at all 55 hospitals in Norway performing such surgery
[31]. We extracted data on the time and date of primary hip
fracture (date of surgery in case of missing information) for
the period January 1, 2005, until December 31, 2010. The
Norwegian Hip Fracture Registry does not contain informa-
tion on the place where fractures occurred, such as a nursing
home.
The Central Population Registry contains demographic
information on the entire population of Norway [27]. We
extracted data on birth year, sex and date of death or emigra-
tion if applicable. All residents of Norway after 1960 have
been assigned a unique 11-digit personal identity number,
which we used to link the selected variables from the various
registries.
Study population
The study population was all residents of Norway born before
1945 and living in Norway on January 1, 2005. We followed
them until the day of any first hip fracture, emigration or death
or until the end of the study period.
Medications studied
We included the following medications in this study:
– ATC code N05B, anxiolytics, main indication: anxiety
& N05BA, benzodiazepine derivates (diazepam, oxazepam,
alprazolam)
& N05BB, other anxiolytics (hydroxyzine)
– ATC code N05C, hypnotics, main indication: sleep
disturbances
& N05CD, benzodiazepine derivates (nitrazepam,
flunitrazepam, midazolam)
& N05CF, benzodiazepine-related drugs (zopiclone,
zolpidem)
& N05CH, melatonin receptor agonists (melatonin)
We excluded the following drugs because of indications
other than anxiety and sleep disturbances or very rare use
(clomethiazole, chlordiazepoxide, lorazepam, bromazepam,
clobazam, meoprobamate, busperione, barbital, flurazepam,
triazolam, zaleplon and scopalamine). We also classified the
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benzodiazepine anxiolytics and hypnotics according to their
half-lives (Table 2, footnote).
Exposure
The DDD is the assumed average maintenance dose per day
for a drug used for its main indication in adults [30]. Pre-
scribed daily dose (PDD) and actual drug consumption vary
within a population. The NorPD does not include information
on PDD or on whether or when the purchasers consumed the
dispensed drugs; we needed to make assumptions about drug
exposure. We calculated the risk of hip fracture for various
assumed total exposure times (3, 7 and 14 days and the
number of days corresponding to the number of DDDs pre-
scribed, respectively; we performed calculations for both 0.5
and 1.0 DDD). We assumed that people started using the
drugs on the day they were purchased and that hypnotics were
taken at bedtime.
We investigated both overall and recently started use of
anxiolytic and hypnotic drugs. We defined overall use as any
exposure to anxiolytics or hypnotics within the study period,
including all exposure periods.We defined recently started use
as the first 14 days of exposure to the drug in question after a
360-day washout period.
Statistical analysis
We compared the incidence of hip fracture during the person-
days exposed and unexposed to anxiolytics and hypnotics
during the study period, by calculating standardized incidence
ratios (SIRs) [29]. If a person received an anxiolytic or hyp-
notic prescription more than once during the study period, all
exposed person-time periods were included in the calcula-
tions. An SIR greater than 1 indicates an increased risk of
hip fracture associated with drug exposure. We adjusted the
SIRs for sex, birth year and time period (divided into 2-month
intervals).
We performed subanalyses for recently started drug use.
Further, we conducted subanalyses for use of hypnotics and
time of fracture, at night (20:00–7:59) or during the day (8:00–
19:59).
We calculated the attributable risk of exposure to anxio-
lytics or hypnotics on hip fracture by dividing the observed
minus the expected number of fractures during the number of
person-days exposed to the drugs in question by the observed
number of fractures in the study population.
Results
The study population comprised 906,422 people with a mean
age of 72.8 years (standard deviation (SD) 8.9 years) on
January 1, 2005 (56%women), and mean follow-up 5.2 years
(SD 1.6). Figure 1 shows an overview of the data sources used
and the data extracted. Altogether, 218,775 people died (53 %
women) and 4,949 emigrated (44 % women).
A total of 204,532 (23 %) people received at least one
prescription for an anxiolytic during the study period; 69 %
were women. Hypnotics were prescribed for 275,372 (30 %)
people; 67 % were women. Z-hypnotics were the drugs most
frequently used (Table 1). More women than men purchased
all drug groups investigated; for both sexes, drug use was
most prevalent among individuals born in 1925–1929 and
1930–1934.
Altogether, 39,938 individuals (mean age 83.0 years; 72 %
women) experienced a primary hip fracture during the study
period. A total of 2,009 fractures (82 % among women)
occurred during exposure to anxiolytics—35 % among those
born in 1915–1924 and 41 % among those born in 1925–
1934. A total of 6,583 fractures (80 % in women) occurred
Norwegian Prescription Database Norwegian Hip Fracture Registry
~ 7.5 million prescriptions
for anxiolytics and hypnotics, 
2004–2010
Central Population Registry
~ 900,000 people born <1945
~ 4.7 million person-years, 
2005–2010
Research database 
~ 40,000 primary hip fractures, 
2005–2010
Fig. 1 Data sources (nationwide
registries) and data extracted for
the research database.
Prescriptions from 2004 needed
to be able to identify users when
the study started (January 1,
2005)
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during exposure to hypnotics—47 % among those born in
1915–1924 and 36 % among those born in 1925–1934. In our
study, 675 people (9 %) were exposed to both anxiolytics and
hypnotics at the time of fracture. The prevalence of hip frac-
ture was higher among exposed women than among exposed
men within all birth cohorts.
The SIRs increased with increasing numbers of assumed
exposed person-days from 3 to 14 days and remained largely
stable when SIR was calculated for the number of days cor-
responding with 0.5 and 1.0 DDD (not shown). Because we
found similar SIRs for 0.5 and 1.0 DDD and wanted to avoid
misclassifying non-users as users, we considered the number
of DDDs the best proxy for drug exposure.
The excess risk of hip fracture was more pronounced
among exposed men than among exposed women. For anxi-
olytics, the SIR was 1.6 (95 % confidence interval (CI) 1.4–
1.7) among men and 1.4 (95 % CI 1.4–1.5) among women
and, for hypnotics, 1.3 (95 % CI 1.2–1.3) and 1.1 (95 % CI
1.1–1.2), respectively. Within all drug groups investigated,
sex differences were most prominent in the youngest cohort
born in 1935–1944 (not shown) and the excess risk of hip
fracture among users decreased with increasing age (Table 2).
The risk of hip fracture was elevated for people exposed to
any anxiolytic (SIR 1.4, 95 % CI 1.4–1.5); the excess risk of
hip fracture was higher among people exposed to short-acting
benzodiazepines (SIR 1.5, 95 % CI 1.4–1.6) than among
people exposed to long-acting benzodiazepines (SIR 1.2,
95%CI 1.2–1.3). Further, the risk of hip fracture was elevated
among people exposed to any hypnotic (SIR 1.2, 95%CI 1.1–
1.2) or z-hypnotics (SIR 1.2, 95 % CI 1.1–1.2), respectively.
Subanalyses for recently started drug use revealed excess
risk of hip fracture for short-acting benzodiazepines (SIR 1.3,
95 % CI 1.0–1.7) and z-hypnotics (SIR 1.2, 95 % CI 1.0–1.5)
only (not shown in tables). The time of hip fracture was
available for 3,323 (51 %) of the people who experienced a
hip fracture during exposure to hypnotics. Z-hypnotics were
associated with higher excess risk of hip fracture at night (SIR
1.3, 95 % CI 1.2–1.4) than during the day (SIR 1.1, 95 % CI
1.1–1.2) (Table 3).
Attributable risk
The share of hip fractures attributable to exposure to anxio-
lytics was estimated at 1.5 % (short-acting benzodiazepines
0.7 % and long-acting benzodiazepines 1.0 %) and exposure
to hypnotics at 2.3 % (z-hypnotics 1.9 %). The attributable
risk of hypnotics was twice as high at night (4.0 %) as during
the day (2.1 %). The corresponding figures regarding z-
hypnotics were 3.3 and 1.7 %, respectively. When all benzo-
diazepines and benzodiazepine-like anxiolytics and hypnotics
were grouped together, the attributable risk was estimated at
3.2 %.
Discussion
We found increased risk of hip fracture in people exposed to
anxiolytics and hypnotics, especially short-acting benzodiaz-
epines. The excess risk of hip fracture associated with hyp-
notics was higher at night than during the day. About 3 % of
all hip fractures were attributable to the use of anxiolytics or
hypnotics.
Benzodiazepines
Our results showing increased risk of hip fracture among users
of benzodiazepine anxiolytics and hypnotics are in accordance
with previous studies [6–9, 32]. This association probably
results from increased risk of falling caused by side effects
such as sedation, impaired balance and reduced cognition [9,
14, 33]. To our knowledge, no evidence indicates that benzo-
diazepines or hypnotics increase the risk of osteoporosis, in
Table 1 Percentage of people in Norway born before 1945 exposed to any anxiolytic or hypnotic drug and various therapeutic subgroups during 2005–
2010. Individuals may have purchased more than one anxiolytic or hypnotic drug
Anxiolytic and hypnotic drugs (percentage of people exposed at least once)
Anxiolytics Hypnotics
Total Benzodiazepine
derivates
Other
anxiolytics
Total Benzodiazepine
derivates
Benzodiazepine-related
drugs
Z-hypnotics
Melatonin receptor
agonists
Total cohort (n=906,422) 22.6 21.0 2.9 30.4 5.2 28.1 1.9
Women (n=506,568) 27.8 26.2 3.3 36.4 6.3 33.6 2.4
Men (n=399,854) 15.9 14.3 2.5 22.8 3.7 21.1 1.3
Anxiolytics, ATC code N05B: benzodiazepine derivates (diazepam, oxazepam, alprazolam) and other anxiolytics (hydroxyzine); Hypnotics, ATC code
N05C: benzodiazepine derivates (nitrazepam, flunitrazepam, midazolam), benzodiazepine-related drugs, z-hypnotics (zopiclone, zolpidem) and
melatonin receptor agonists (melatonin)
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contrast to other psychotropic drugs such as antidepressants
and antipsychotics [34].
Whether short-acting benzodiazepines or long-acting ben-
zodiazepines pose the greatest risk of hip fracture is unclear
[9]. Heterogeneity in study populations, study designs and
drug groups investigated hampers comparisons [35]. A recent
literature review including studies in Europe and the USA [9]
revealed pooled relative risks of hip fracture of 1.23 for short-
acting benzodiazepine and z-hypnotic users and 1.32 for long-
acting benzodiazepine users. On the other hand, attributable
risks were highest regarding short-acting benzodiazepines and
z-hypnotics, since these were most widely used [9]. In a recent
meta-analysis, the use of benzodiazepines, especially short-
acting benzodiazepines, was associated with a statistically and
Table 2 Comparison of number of hip fractures (n) during exposed and
unexposed person-time (standardized incidence ratio (SIR), 95 % CI) in
the population of Norway born before 1945 and exposed to various
anxiolytic and hypnotic drugs in 2005–2010, by sex and birth cohort
(exposed person-days, DDD)
Anxiolytics Hypnotics Combination
Anxiolytics (total) Short-acting
benzodiazepines
Long-acting
benzodiazepines
Hypnotics (total) Z-hypnotics Any benzodiazepine
or benzodiazepine-
like drug
n SIR n SIR n SIR n SIR n SIR n SIR
Total cohort 2,009 1.4 (1.4–1.5) 896 1.5 (1.4–1.6) 2,141 1.2 (1.2–1.3) 6,583 1.2 (1.1–1.2) 5,418 1.2 (1.1–1.2) 7,814 1.2 (1.2–1.2)
By sex
Women 1,642 1.4 (1.4–1.5) 739 1.4 (1.3–1.5) 1,743 1.2 (1.2–1.3) 5,274 1.1 (1.1–1.2) 4,326 1.1 (1.1–1.2) 6,273 1.2 (1.1–1.2)
Men 367 1.6 (1.4–1.7) 157 1.7 (1.5–2.0) 398 1.3 (1.2–1.5) 1,309 1.3 (1.2–1.3) 1,092 1.3 (1.2–1.4) 1,541 1.3 (1.2–1.4)
By birth cohort
1935–1944 410 2.7 (2.4–3.0) 148 2.4 (2.1–2.8) 349 2.6 (2.3–2.9) 787 2.0 (1.8–2.1) 676 1.9 (1.8–2.1) 1,020 2.1 (2.0–2.3)
1925–1934 819 1.6 (1.5–1.7) 343 1.6 (1.4–1.7) 774 1.4 (1.3–1.5) 2,341 1.3 (1.2–1.3) 1,986 1.3 (1.2–1.3) 2,844 1.3 (1.3–1.4)
1915–1924 712 1.1 (1.0–1.2) 369 1.2 (1.1–1.3) 890 1.0 (0.9–1.0) 3,098 1.0 (1.0–1.0) 2,501 1.0 (1.0–1.0) 3,552 1.0 (1.0–1.0)
<1915 68 1.1 (0.9–1.4) 36 1.2 (0.9–1.7) 128 1.1 (0.9–1.3) 357 1.0 (0.9–1.1) 255 1.0 (0.9–1.1) 398 1.0 (0.9–1.1)
Attributable risk (% of hip fractures during DDD exposure throughout the study period)
1.5 0.7 1.0 2.3 1.9 3.2
Anxiolytics, ATC code N05B: benzodiazepine derivates (diazepam, oxazepam, alprazolam) and other anxiolytics (hydroxyzine); Hypnotics, ATC code
N05C: benzodiazepine derivates (nitrazepam, flunitrazepam, midazolam), benzodiazepine-related drugs or z-hypnotics (zopiclone, zolpidem) and
melatonin receptor agonists (melatonin); Short-acting benzodiazepines, half-life <24 h: oxazepam, alprazolam and midazolam; Long-acting
benzodiazepines, half-life >24 h: diazepam, nitrazepam and flunitrazepam; Any benzodiazepine or benzodiazepine-like drug: short-acting benzodiaz-
epines+long-acting benzodiazepines+z-hypnotics (zopiclone, zolpidem)
Table 3 Comparison of daytime (08:00–19:59) and nighttime (20:00–
07:59) observed number of hip fractures (n) and excess risk of hip fracture
(standardized incidence ratio (SIR), 95%CI) in the population of Norway
born before 1945 exposed to hypnotics in 2005–2010 (exposure 7 days,
14 days and DDD)
Hypnotics (total) Hypnotics daya Hypnotics nighta Z-hypnotics daya Z-hypnotics nighta
n SIR n SIR n SIR n SIR n SIR
Exposed person-days
7 1,050 1.3 (1.2–1.5) 346 1.2 (1.1–1.3) 172 1.4 (1.2–1.6) 294 1.2 (1.1–1.4) 142 1.4 (1.2–1.6)
14 2,071 1.3 (1.2–1.3) 678 1.2 (1.1–1.3) 340 1.4 (1.3–1.6) 574 1.2 (1.1–1.4) 277 1.4 (1.2–1.5)
DDD 6,583 1.2 (1.1–1.2) 2,245 1.1 (1.1–1.2) 1,078 1.3 (1.2–1.4) 1,835 1.1 (1.1–1.2) 884 1.3 (1.2–1.4)
Attributable risk (% of hip fractures during DDD exposure throughout the study period)
2.3 2.1 4.0 1.7 3.3
Hypnotics, ATC code N05C: benzodiazepine derivates (nitrazepam, flunitrazepam,midazolam), benzodiazepine-related drugs or z-hypnotics (zopiclone,
zolpidem) and melatonin receptor agonists (melatonin); Z-hypnotics, ATC code N05CF: benzodiazepine-related drugs (zopiclone, zolpidem)
a Time of fracture known in 51 % of cases (hip fractures occurring during exposure to hypnotic drugs)
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clinically significantly increased risk of any fracture; the rel-
ative risk of hip fracture was 1.35 among users of any benzo-
diazepines [10].
We analysed short-acting benzodiazepines, long-acting
benzodiazepines and z-hypnotics separately and found that
the excess risk of hip fracture was higher among people using
short-acting benzodiazepines than among those using long-
acting benzodiazepines or z-hypnotics.
In accordance with previous studies, we found an increased
risk of hip fracture associated with recently started use of
short-acting benzodiazepines [36]. Growing evidence indi-
cates a dose–response curve for fracture risk, starting already
at very low (0.2 DDD) drug dosages [6, 37,
38]. Guidelines recommend non-pharmaceutical treat-
ment options in anxiety of mild to moderate severity
and insomnia and low dosages and short duration only
when prescribing [17]. Still, benzodiazepines and
z-hypnotics are commonly prescribed for older people
at higher dosages and for longer periods [16].
Z-hypnotics
The elevated risk of hip fracture identified among people
using z-hypnotics is in accordance with previous studies [14,
39]. Z-hypnotics have previously been considered less harm-
ful [11], and there has been an intentional shift from benzodi-
azepines to z-hypnotics. Nevertheless, observational studies
suggest that z-hypnotics are not safer regarding falls
[12] or hip fractures [13, 14], probably by inducing or
worsening impairment of balance and cognition. Further,
the effectiveness of z-hypnotics is limited among people
aged 60 years or older, which has led to a great con-
troversy on the use of these drugs among older people
[24]. Cognitive behavioural therapy (including, e.g.
stimulus control and sleep restriction), on the other
hand, is highly effective [40].
We found an increased risk of hip fracture during the
first 14 days among previous non-users, in agreement
with Berry et al. [39], suggesting that short-term use
may also be harmful. Our findings are clinically rele-
vant because z-hypnotics are widely prescribed to (very)
old people [41]. Their significance is further underlined
by z-hypnotics being associated with the greatest overall
impact on attributable risk estimates.
Time of fracture
One may hypothesize that hypnotics protect against falls and
hip fracture at night because the people taking these drugs
would sleep and not stand up and use the bathroom. Never-
theless, z-hypnotics may cause balance impairment and con-
fusion on awakening and thus increased risk of falls and hip
fracture [12]. A previous study investigating diurnal
fracture patterns has shown a daytime peak [42]. Among
people with or without dementia using psychotropic
drugs, this diurnal pattern was lacking, probably be-
cause of increased fracture risk at night [42]. In accor-
dance with that study, we found higher excess risk and
higher attributable risk of hip fracture associated with z-
hypnotics at night than during the day.
Age
Generally, we found the excess risk of hip fracture to be
most evident within the youngest cohorts. We probably
underestimated the risk of hip fracture among the oldest
old because of two methodological issues discussed
below: the lack of clinical information (confounding
factors could not be adjusted for) and the systematic
misclassification of the highly exposed [27] nursing
home patients as drug non-users.
Methodological considerations
The national health registries provided a unique opportunity to
link complete data on anxiolytics and hypnotics purchased by an
unselected community-dwelling older populationwith all primary
hip fractures registered in Norway. The 6-year follow-up period,
with all exposure periods included, revealed high numbers of
cases, and the nationwide prospective study design prevented
selection and information bias. Randomized controlled trials
comparing short-acting benzodiazepines and long-acting benzo-
diazepines are not likely to be performed for ethical reasons.
The databases used have some limitations. The NorPD lacks
individual information on medication dispensed to people liv-
ing in nursing homes, leading to systematic misclassification of
about 40,000 people at any time as drug non-users. Because
nursing home residents have a high prevalence of both hip
fracture and anxiolytic and hypnotic drug use [43], the excess
risk of hip fracture has been underestimated among exposed
people. The Norwegian Hip Fracture Registry comprises more
than 80 % of all hip fracture operations in Norway [26], being
somewhat less complete during the first years. The time of
fracture was available in half the cases. There is no reason to
suspect systematically biased underreporting; we found that
about two thirds of the eligible cases occurred during daytime,
in accordance with a recent study in Sweden [42].
A study in Sweden revealed the PDDs to be 0.42 for
anxiolytics and 0.64 for hypnotics, respectively [44]. Our
calculations based on drug exposure corresponding with 1.0
DDDmay therefore have revealed conservative risk estimates.
However, we wanted to avoid misclassifying non-users as
users.
The Norwegian Hip Fracture Registry lacks information on
other clinical conditions. Many factors may influence the risk
of falls and fractures, such as acute and chronic somatic and
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mental health conditions, sleep disturbances and physical
activity at night, balance impairment, frailty, lifestyle and
concomitant drug use [45]. Nevertheless, previous studies
have shown the excess risk of hip fracture associated with
anxiolytics and hypnotics to remain when adjusting for cog-
nitive and functional status, BMI and smoking [46], and
concomitant drug use [8]. Thus, we chose not to adjust for
concomitant drug use, which would also have introduced
further uncertainty (due to the lack of clinical information).
There is no reason to suspect that the findings in this nation-
wide study should not be generalisable to other countries.
Conclusion
Our nationwide, prospective study adds important knowledge
on the excess risk of hip fracture for users of short-acting
benzodiazepines and z-hypnotics, which were previously con-
sidered less harmful for use among older people. Since hip
fractures are highly prevalent in this population, even a minor
excess risk may cause great numbers of hip fractures, with
major clinical and economic consequences.
Our results emphasize the need for careful consideration in
treating old people with anxiety or insomnia. Growing evi-
dence implies no reason to prefer short-acting benzodiazepines
to long-acting benzodiazepine anxiolytics or z-hypnotics to
benzodiazepine hypnotics with regard to the risk of hip fracture
because even short-term use of these drugs is associated with
increased risk. Thus, non-pharmaceutical treatment options
should be given priority and efforts should be made to reduce
dosages and withdraw drugs from long-term users. We found
people using z-hypnotics to be at greatest risk at night; this
association deserves further investigation.
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